関連する実験動画
Updated: May 30, 2026

11:56
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
Published on: October 25, 2013
二重D-Ala-D-alaとD-Ala-D-Lac結合のために設計された再設計されたバンコマイシンは,バンコマイシン耐性細菌に対する強力な抗菌活性を示しています
Jian Xie1, Joshua G Pierce, Robert C James
1Department of Chemistry, The Skaggs Institute for Chemical Biology, La Jolla, California 92037, United States.
Journal of the American Chemical Society
|August 10, 2011
まとめ
新型バンコマイシン誘導体である[Ψ[C[NH]NH]Tpg[4]バンコマイシンアグリコンは,d-Ala-d-Alaとd-Ala-d-Lacの標的の両方に結合することによって,バンコマイシン耐性細菌に対する抗菌活性を再生します.
科学分野:
- 微生物学 微生物学とは
- 薬用化学 薬用化学について
- ドラッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー
背景:
- バクテリアのヴァンコマイシン耐性は,世界的な健康上の重大な脅威です.
- 耐性細菌は細胞壁の前駆物質を変化させ,バンコマイシンの有効性を低下させます.
- ペプチドグリカンのd-Ala-d-Lac変異は,バンコマイシン耐性の重要なメカニズムである.
研究 の 目的:
- 二重結合能力を持つバンコマイシン誘導体を設計・合成する.
- バンコマイシン耐性菌株に対する抗微生物活性を再生する.
- 耐性感染症と闘うための新しい治療戦略を開発する.
主な方法:
- [Ψ[C[(NH) NH]Tpg[(4) ]ヴァンコマイシンアグリコンの化学合成.
- d-Ala-d-Alaとd-Ala-d-Lacリガンドによる結合親和性アッセイ.
- バンコマイシン耐性エンテロコチ (VRE) に対する抗菌活性検査.
主要な成果:
- 新型派生物は,d-Ala-d-Alaとd-Ala-d-Lac.の両方に強い結合を示した.
- d-Ala-d-Lacに対する結合親和性は,バンコミシンアグリコンと比較して有意に増加した.
- 強力な抗微生物活性がVanA VREに対して示され,最小抑制濃度 (MIC) は0.31μg/mlであった.
結論:
- バンコマイシンの単一の原子改変は,抵抗機構を克服することができます.
- 設計されたデリバティブは,バンコマイシン耐性細菌感染症の治療に有望なアプローチを提供します.
- この戦略は,次世代の抗生物質を開発するための合理的な基盤を提供します.
関連する概念動画
Inhibitors of Gram-positive Cell Wall Synthesis
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Antibiotic Selection
Overview
Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...

